My research group focuses on the identification, characterisation and validation of novel drug targets for the treatment of the major acute and chronic CNS pathologies. We also are developing novel all-in-one behavioural tests for both animals and humans.

Dr Chazot has developed two new clinical development programmes over the last 20 years, one for chronic pain (Votucalis), and one for Alzheimer’s Disease (PBM-T 1068nm), the former at the pipeline stage for the company Akari Therapeutics UK, and the latter reaching the FDA Phase 2b clinical stage in the US. He is also the key academic collaborator for the Durham University spin-out company Nevrargenics, (http://nevrargenics.com), who has developed exciting new rational drug leads (RAR-M) for disease-modification in a range of neurodegenerative diseases.